Skip to main content
OpenTrials

Clinical trial condition

Waldenstrom Macroglobulinemia

Explore clinical trials studying Waldenstrom Macroglobulinemia. Study availability and eligibility vary by location and protocol.

394 public trials 46 recruiting studies
Refine in advanced search Browse all conditions

Waldenstrom Macroglobulinemia trial results

Active, Not Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details
Active, Not Recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Active, Not Recruiting

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia

NCT04624906

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Vancouver General Hospital Vancouver, British Columbia, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
View Trial Details
Active, Not Recruiting

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

NCT06441214

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations
  • A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia Alessandria, Italy
  • A.O.U. Ospedali Riuniti - Clinica di Ematologia Ancona, Italy
  • Ospedale C. e G. Mazzoni - U.O.C. di Ematologia Ascoli Piceno, Italy
  • AOU Policlinico Consorziale - U.O. Ematologia con Trapianto Bari, Italy
View all 28 locations
View Trial Details
Active, Not Recruiting

A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia

NCT05952037

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Medstar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • University of Miami Miami, Florida, United States
View all 72 locations
View Trial Details
Active, Not Recruiting

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

NCT03620903

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Studiengesellschaft Onkologie Bielefeld GbR Bielefeld, Germany
  • DIAKO Ev. Diakonie-Krankenhaus gGmbH, Med. Klinik II Bremen, Germany
  • Universitätsklinikum Halle, Klinik für Innere Medizin IV Halle, Germany
  • Universtätsmedizin Mannheim, III. Medizinische Klinik Studienzentrale im MCC Mannheim, Germany
View Trial Details

Related conditions